A Good Cancer research Bio company? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Good Cancer research Bio company?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: B. Ino who wrote ()	9/19/1996 10:24:00 AM
From: Henry Niman	of 76

The FDA approval of RU-486 is front page news across the country. I'm not sure if this news is sparking LGND higher this morning, but buyers are out early and pushing the price to 15 7/8 on volume topping 70,000 in the first 1/2 hour. LGND has extensive anti-progestin programs (prinicipally through its alliance and licensing with AHP's subsidiary, Wyeth Ayerst). This is part of a broad women's health program and targets many diseases (including cancer and endometriosis). The RU-486 approval will make it easier for 2nd and 3rd generation anti-progestins to gain FDA approval. LGND develops progersterone antagonists as well as agonist. AHP has licensed LG1447 (antagonist) as well as LG2527 and LG2716 (agonist) series.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next